Canadian Journal of Public Health

, Volume 99, Issue 5, pp 391–396 | Cite as

Costs for Tuberculosis Care in Canada

  • Dick Menzies
  • Megan Lewis
  • Olivia Oxlade



We have estimated tuberculosis (TB)-related expenditures by governments and other third parties in Canada in 2004, in order to compare spending on different activities, by various jurisdictions, and in different regions.


To ascertain health system costs (including public health costs), a self-administered questionnaire was completed by all federal, provincial, and territorial health departments and laboratories involved in TB activities and a sample of local health departments. Hospitalization information was obtained from the Canadian Institute for Health Information, while costs for care were derived from published literature. Costs borne by patients and families were not included. All costs were ascertained for 2004 and expressed in Canadian dollars.


In 2004, total TB-related expenditures in Canada were $74 million, equivalent to $47,290 for every active TB case diagnosed in that year. Research accounted for $4.5 million (or 6% of the total). Non-research-related federal spending accounted for $16.3 million (22%) and provincial/territorial expenditures accounted for $53.1 million (72%). Active tuberculosis accounted for $31 million or 59% of provincial/territorial expenditures. There were substantial regional differences in TB-related expenditures; the highest expenditures were in the Northern Territories ($72,441 per active TB case), followed by the four Western provinces ($35,914), and lowest in the Atlantic provinces ($28,259).


Total TB-related expenditures in Canada in 2004 were considerable, of which almost 60% were for curative services and only 40% for prevention and control activities. Regional differences likely reflect differences in accessibility of the populations to health care services, and greater interventions in communities with ongoing TB transmission.

Key words

TB control; costs for control; public health costs; TB costs 



Nous avons estimé les sommes consacrées à la lutte antituberculeuse par les gouvernements et d’autres organismes au Canada en 2004 afin de comparer les dépenses par activité, par province ou territoire et par région.


Pour vérifier les coûts du système de santé (y compris les coûts de santé publique), nous avons envoyé un questionnaire à tous les services de santé et laboratoires fédéraux, provinciaux et territoriaux intervenant dans les activités antituberculeuses et à un échantillon de services de santé locaux. L’Institut canadien d’information sur la santé nous a communiqué les données sur les hospitalisations, et nous avons estimé les coûts des soins d’après les études publiées sur le sujet. Les coûts défrayés par les patients et les familles n’ont pas été comptabilisés. Tous les coûts visent l’année 2004 et sont exprimés en dollars canadiens.


En 2004, les dépenses liées à la tuberculose au Canada se sont chiffrées à 74 millions de dollars (M$), soit 47 290 $ par cas de tuberculose active diagnostiqué pendant l’année. La recherche a coûté 4,5 M$ (6 % du total). Les dépenses fédérales non liées à la recherche ont représenté 16,3 M$ (22 %), et les dépenses provinciales et territoriales, 53,1 M$ (72 %). La tuberculose active a coûté 31 M$, soit 59 % des dépenses provinciales et territoriales. On note d’importants écarts régionaux dans les dépenses liées à la tuberculose; les plus élevées ont été enregistrées dans les territoires nordiques (72 441 $ par cas de tuberculose active) et dans les quatre provinces de l’Ouest (35 914 $), et les dépenses les plus faibles, dans les provinces de l’Atlantique (28 259 $).


Les dépenses totales liées à la tuberculose au Canada en 2004 ont été considérables; près de 60 % ont été consacrées aux services de soins, et 40 % seulement aux activités de prévention et de contrôle. Les écarts régionaux reflètent probablement les différences dans l’accès des populations aux services de santé et les interventions plus poussées dans les localités où la tuberculose est endémique.

Mots clés

lutte antituberculeuse coûts des interventions coûts de santé publique coûts de la tuberculose 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ellis E, Sauvé L, Phypers M, Sheardown C, Allegakone M. Tuberculosis in Canada. Ottawa, ON: Public Health Agency of Canada, 2004. Available online at publicat/tbcan02/index.html (Accessed July 2007).Google Scholar
  2. 2.
    Long R, Njoo H, Hershfield E. Tuberculosis: 3. Epidemiology of the disease in Canada. CMAJ 1999;160(8):1185–90.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Ontario Case Costing Initiative. 2004. Available online at: (Accessed November 2005).
  4. 4.
    Canadian Institutes for Health Information. Health Indicators. 2005;28. Statistics Canada, editor. Available online at: cihiweb/dispPage.jsp?cw_page=process_ download_form_e (Accessed July 2007).Google Scholar
  5. 5.
    Dasgupta K, Schwartzman K, Marchand R, Tannenbaum TN, Brassard P, Menzies D. Comparison of cost effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000;162(6):2079–86.CrossRefGoogle Scholar
  6. 6.
    Bank of Canada. Inflation calculator. 2005. Available online at: (Accessed March 4, 2005).Google Scholar
  7. 7.
    Ellis E, Medaglia A, Phypers M, Sheardown C. Tuberculosis: Drug resistance in Canada, 2002: Reported susceptibility results of the Canadian Tuberculosis Laboratory Surveillance System. Health Canada, 2003.Google Scholar
  8. 8.
    Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-van Weezenbeek CS, et al. Increasing transparency in partnerships for health - introducing the Green Light Committee. Trop Med Int Health 2002;7:970–76.CrossRefGoogle Scholar
  9. 9.
    Long R. Canadian Tuberculosis Standards. 2000/2001 edition. Toronto, ON: Canadian Lung Association, 2000.Google Scholar
  10. 10.
    BC Centre for Disease Control. Annual Report Tuberculosis Control in 2002. Vancouver, BC: BC Ministry of Health, 2003.Google Scholar
  11. 11.
    Blum RN, Polish LB, Tapy JM, Catlin BJ, Cohn DL. Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status. Chest 1993;103:1670–74.CrossRefGoogle Scholar
  12. 12.
    Onofre Moran-Mendoza A. The value of the tuberculin skin test size in predicting the development of tuberculosis in contacts of active cases. Department of Health Care and Epidemiology, University of British Columbia, 2004.Google Scholar
  13. 13.
    Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: Outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003;7(12):S384–S390.PubMedGoogle Scholar
  14. 14.
    Adhikari N, Menzies R. Community-based tuberculin screening in Montreal: A cost-outcome description. Am J Public Health 1995;85(6):786–90.CrossRefGoogle Scholar
  15. 15.
    Chee CBE, Boudville IC, Chan SP, Zee YK, Wang YT. Patient and disease characteristics, and outcome of treatment defaulters from the Singapore TB control unit - a one-year retrospective survey. Int J Tuberc Lung Dis 2000;4(6):496–503.PubMedGoogle Scholar
  16. 16.
    Treasury Board of Canada. Rates of Pay - Policies and Guidelines. 2006. Available online at: (Accessed February 15, 2006).Google Scholar
  17. 17.
    Canadian Institute for Health Information. Available online at: dispPage.jsp?cw_page=home_e (Accessed August 2004).
  18. 18.
    Khan K, Muennig P, Behta M, Pharm D, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347(23):1850–59.CrossRefGoogle Scholar
  19. 19.
    Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, Nicola RM, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995;155:1595–600.CrossRefGoogle Scholar
  20. 20.
    Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000;161:780–89.CrossRefGoogle Scholar
  21. 21.
    Demeter SJ, Jacobs P, Chmielowie C, Logus W, Hailey D, Fassbender K, et al. The cost of lung cancer in Alberta. Can Respir J 2007;14:81–86.CrossRefGoogle Scholar
  22. 22.
    Nguyen D, Proulx JF, Westley J, Thibert L, Dery S, Behr MA. Tuberculosis in the Inuit community of Quebec, Canada. Am J Respir Crit Care Med 2003;168(11):1353–57.CrossRefGoogle Scholar
  23. 23.
    Greenaway C, Menzies D, Fanning A, Grewal R, Yuan L, FitzGerald JM. Delay in diagnosis among hospitalized patients with active tuberculosis—predictors and outcomes. Am J Respir Crit Care Med 2002;165(7):927–33.CrossRefGoogle Scholar
  24. 24.
    Wurtz R, White RW. The cost of tuberculosis: Utilization and estimated changes for the diagnosis and treatment of tuberculosis in a public health system. Int J Tuberc Lung Dis 1999;3(5):382–87.PubMedGoogle Scholar
  25. 25.
    Arno PS, Murray CJL, Bonuck KA, Alcabes P. The economic impact of tuberculosis in hospitals in New York City: A preliminary analysis. J Law Med Ethics 1993;21:317–23.CrossRefGoogle Scholar
  26. 26.
    Long R, Zielinski M, Kunimoto D, Manfreda J. The emergency department is a determinant point of contact of tuberculosis patients prior to diagnosis. Int J Tuberc Lung Dis 2002;6(4):332–39.PubMedGoogle Scholar
  27. 27.
    Moran GJ, McCabe F, Morgan MT, Talan DA. Delayed recognition and infection control for tuberculosis patients in the emergency department. Ann Emerg Med 1995;26(3):290–95.CrossRefGoogle Scholar
  28. 28.
    Venkatarama KR, Iademarco EP, Fraser VJ, Kollef MH. Delays in the suspicion and treatment of tuberculosis among hospitalized patients. Ann Intern Med 1999;130:404–11.CrossRefGoogle Scholar
  29. 29.
    Liam CK, Tang BG. Delay in the diagnosis and treatment of pulmonary tuberculosis in patients attending a university teaching hospital. Int J Tuberc Lung Dis 1997;1(4):326–32.PubMedGoogle Scholar
  30. 30.
    Naalsund A, Heldal E, Johansen B, Kongerud J, Boe J. Deaths from pulmonary tuberculosis in a low-incidence country. J Intern Med 1994;236:137–42.CrossRefGoogle Scholar
  31. 31.
    Schwartzman K, Oxlade O, Barr G, Grimard F, Acosta I, Baez J, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005;353:1008–20.CrossRefGoogle Scholar

Copyright information

© The Canadian Public Health Association 2008

Authors and Affiliations

  1. 1.Respiratory Epidemiology and Clinical Research Unit, Montreal Chest InstituteMcGill UniversityMontrealCanada

Personalised recommendations